Sign inJoin waitlistJoin the waitlist

Hans-Peter Kiem

Director · University of Washington School of Medicine

Credentials: · · ·

History

Hematological Malignancies Program · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
1990–1993
Internal Medicine
Vanderbilt University Medical Center
1987–1990
Universität Ulm Medizinische Fakultät
1983–1987

Research

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
Cell · 2020 · 1,860 citations
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
Blood · 2001 · 1,146 citations
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
Nature · 2014 · 1,091 citations

Rainer Storb
42 papers
Joachim Deeg
23 papers
Keith Jerome
22 papers
RN
Richard Nash
19 papers
Frederick Appelbaum
18 papers
Brenda Sandmaier
16 papers
Paul Martin
15 papers
Mary Flowers
14 papers
RA
Robert Andrews
13 papers
David Maloney
12 papers
David Rawlings
12 papers
George Georges
12 papers

Grants

Regulated, Long-Term Expression of Anti-HIV Antibodies via B Cell Receptor-Targeted Lentiviral Transduction
National Institute of Allergy and Infectious Diseases · R01
PI · $5.9M · University of California Los Angeles
2026–2030
In vivo Cell Engineering for HIV Cure.
National Heart, Lung, and Blood Institute · P01
PI · $7.4M · University of Southern California
2025–2030
In vivo Gene Therapy for Hemoglobinopathies with Multiplexed Virus-Like Particles
National Heart, Lung, and Blood Institute · R01
Contact PI · $7.7M · Fred Hutchinson Cancer Center
2017–2030
In vivo Gene Therapy for Fanconi Anemia
National Heart, Lung, and Blood Institute · R01
Contact PI · $4.1M · Fred Hutchinson Cancer Center
2019–2030

Clinical trials

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Principal investigator · Withdrawn · Phase 1
Fred Hutchinson Cancer Center
2016–2019
Gene Therapy for Fanconi Anemia
Principal investigator · Terminated · Phase 1
Fred Hutchinson Cancer Center
2012–2024
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Principal investigator · Terminated · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2009–2021
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia
Principal investigator · Completed · Phase 2
Fred Hutchinson Cancer Center
2007–2013